A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia



Status:Completed
Conditions:Cancer, Cancer, Cancer, Cancer, Blood Cancer, Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:3/1/2019
Start Date:April 1, 2014
End Date:July 31, 2017

Use our guide to learn which trials are right for you!

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 232 Alone and in Combination With Trametinib in Adult Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Open-label, sequential dose escalation and expansion study of AMG 232 in subjects with acute
myeloid leukemia.


Inclusion Criteria:

- Men or women > 18 years old

- Pathologically-documented, definitively-diagnosed AML that is relapsed or refractory
to standard treatment, for which no standard therapy is available or the subject
refuses standard therapy

- Ability to take oral medications and willing to record daily adherance to
investigational product

- Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria:

- Active infection requiring intravenous (IV) antibiotics

- Prior participation in an investigational study (procedure or device) within 21 days
of study day 1

- Major surgery within 28 days of study day 1

- Anti-tumor therapy within 14 days of study day 1
We found this trial at
5
sites
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
1056
mi
from
Buffalo, NY
Click here to add this to my saved trials
Charlotte, North Carolina 28207
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials